MedTrace Logo

The Tracking Molecular Evolution for NSCLC (T-MENC) Study

NCT03838588 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-02-12

No results posted yet for this study

Summary

Tumor genomic clonal evolution assessed with liquid biopsy of stage IB,II and IIIA non-small cell lung cancer patients after getting radical resection. Plasma circulating tumor DNA (ctDNA) analysis detects molecule residual disease and predicts recurrence in patients. The concordance of the relative abundance of mutations in plasma ctDNA with cancer recurrence.

Conditions

  • Lung Neoplasms
  • Lung Cancer
  • Nonsmall Cell Lung Cancer
  • Adenocarcinoma of Lung

Sponsors & Collaborators

  • Xuanwu Hospital, Beijing

    collaborator OTHER

  • Geneplus-Beijing Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Yi Zhang, MD · Xuanwu Hospital, Beijing

  • Yao guang Sun, MD · Beijing Hospital

  • Jie Li, MD · Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China +86-139 1189 2587 [email protected]

  • Hong Zhang, MD · The First Hospital of Jilin University

  • Zhi qiang Wang, MD · Tangshan People's Hospital

  • Ming He, MD · Beijing Chest Hospital, Capital Medical University

  • Zi dan Wang, MD · Beijing Chest Hospital, Capital Medical University

  • Li jun Liu, MD · Hebei General Hospital

  • Kang Shao, MD · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Chao yang Liang · China-Japan Friendship Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-06
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03838588 on ClinicalTrials.gov